Debiopharm and Alkyon link for radioligand therapies development
Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted radioligand therapies (RLTs). The…
All articles by
-
-
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat…
-
Echosens and Boehringer expand partnership for MASH diagnosis
Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care.…
-
Antares Therapeutics gains $177m for cancer medicines development
Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer…
-
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive…
-
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower…
-
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for…
-
Aytu BioPharma to commercialise Exxua for MDD in the US
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to…
-
Juvenescence enhances AI drug discovery with Ro5 acquisition
Juvenescence has acquired drug discovery company Ro5, a move that enhances its AI/machine learning capabilities and improves research and development…
-
Akeso gains NMPA approval for cadonilimab to treat cervical cancer
China’s National Medical Products Administration (NMPA) has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic cervical…